Figure 1
CONSORT diagram for the CA180-034 study. One of the 167 patients treated with dasatinib 50 mg twice daily had been randomly assigned to receive 100 mg once daily. Adapted from Shah et al9 and reproduced with permission from the American Society of Clinical Oncology. (*) Reasons for discontinuation are presented in Table 1.
